Amneal Pharmaceuticals (AMRX) vs TG Therapeutics (TGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Amneal Pharmaceuticals (AMRX) has outperformed TG Therapeutics (TGTX) over the past year, gaining 89.7% versus a gain of 49.2%. Over five years, AMRX leads with a +248.4% price change compared with +60.1% for TGTX. TG Therapeutics is the larger company by market cap ($8.17 billion vs $6.84 billion), about 1.2 times the size.
On valuation, Amneal Pharmaceuticals trades at a lower forward P/E (16.5x vs 19.7x for TG Therapeutics). TG Therapeutics converts more of its revenue into profit, with a net margin of 72.6% versus 2.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRX | TGTX |
|---|---|---|
| Share price | $19.65 | $53.34 |
| Market cap | $6.84B | $8.17B |
| 1-day change | 0.00% | +0.74% |
| YTD return | +55.95% | +78.93% |
| 1-year return | +89.67% | +49.20% |
| 5-year return | +248.40% | +60.13% |
| P/E ratio (TTM) | 40.10 | 19.40 |
| Forward P/E | 16.48 | 19.70 |
| EPS (TTM) | $0.49 | $2.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.02B | $616.29M |
| Revenue growth (YoY) | +8.05% | +87.32% |
| Net income (latest FY) | $72.06M | $447.18M |
| Gross margin | 36.88% | 83.66% |
| Operating margin | 13.05% | 20.01% |
| Net margin | 2.39% | 72.56% |
| 52-week high | $21.18 | $59.30 |
| 52-week low | $9.56 | $26.76 |
| Distance from 52-week high | -7.20% | -10.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +15.57% | +30.69% |
| Average volume | 2.26M | 2.01M |
| Shares outstanding | 348.30M | 153.08M |
| Employees | 8,700 | 399 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRX has outperformed TGTX by 40.5 percentage points over the past year.
- Amneal Pharmaceuticals trades at a higher earnings multiple (40.1x vs 19.4x trailing P/E).
- TG Therapeutics is more profitable, keeping 72.6 cents of every revenue dollar as net income versus 2.4 cents for Amneal Pharmaceuticals.
- TG Therapeutics grew revenue faster in its latest fiscal year (+87.32% vs +8.05%).
About Amneal Pharmaceuticals
AMRX stock →Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees
About TG Therapeutics
TGTX stock →TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees
AMRX vs TGTX FAQ
Which is bigger, Amneal Pharmaceuticals or TG Therapeutics?
TG Therapeutics (TGTX) is larger, with a market capitalization of $8.17B compared with $6.84B for Amneal Pharmaceuticals (AMRX).
Which stock has performed better over the past year, AMRX or TGTX?
AMRX returned +89.67% over the past 12 months, compared with +49.20% for TGTX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMRX or TGTX?
TGTX has the lower trailing P/E at 19.4, versus 40.1 for AMRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Amneal Pharmaceuticals and TG Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.